EUVIMEDEUVIMED entdecken
Scoping Review

Vaccine‐Mediated Immunity in Survivors of Childhood Cancer: A Scoping Review

Sophie Junak iD, Marcela Algave, Melissa Beauchemin, Ruth Masterson Creber, Ulf G Bronas

Pediatric Blood & Cancer · 2026-07 · 73 (7)

DOI: 10.1002/1545-5017.70319 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 11.04.2026. Verfasst von Sophie Junak und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Nursing, Columbia University, New York, New York, USA. Hauptthemen laut MEDLINE: Neoplasms, Cancer Survivors, Vaccination, Immunity, Humoral. Die Arbeit nennt 52 Literaturangaben. Gefördert von: The National Institute of Nursing Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advances in childhood cancer treatment have dramatically improved survivorship such that ∼1 in 500 Americans is a survivor of childhood cancer. Although short‐term treatment effects are well documented, late effects on humoral immunity remain underexplored. Declining general vaccination rates, combined with under‐protection among survivors, heightens the risk for vaccine‐preventable diseases (VPDs) in this population. A scoping review was conducted on three research databases (PubMed, Embase, and Web of Science) following the Joanna Briggs Institute systematic methodology and Preferred Reporting Items for Systematic Reviews and Meta‐Analyses Extension for Scoping Reviews guidelines. Eligible studies included survivors aged 0–21 at diagnosis treated with non‐transplant cancer therapies that reported humoral immune outcomes (titers, CD4, and IgG recovery). Twenty‐three studies were included. All studies reported loss of immunity to at least one VPD following cancer treatment. Inactivated vaccines showed low posttreatment protection (≤50%) but strong recovery following revaccination (≥90%). Live attenuated vaccines demonstrated inconsistent baseline protection (9%–75%), with postvaccination immunity averaging ∼72%. Younger age at diagnosis was most consistently associated with reduced immunity, whereas disease type and treatment intensity were less reliably linked. Pediatric cancer survivors frequently lack protective immunity to VPDs following treatment. Revaccination with inactivated vaccines appears effective, but responses to live attenuated vaccines remain suboptimal.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsCancer SurvivorsVaccinationImmunity, HumoralHumansChildChild, PreschoolInfantAdolescentInfant, NewbornYoung Adult

Stichwörter der Autor:innen

cancer survivorchildhumoral immunityvaccination

Autor:innen und Institutionen

  • School of Nursing, Columbia University, New York, New York, USA.

ORCID-Profile: Sophie Junak

Förderung

  • The National Institute of Nursing Research

Zitieren

APA

Junak, S., Algave, M., Beauchemin, M., Creber, R. M., & Bronas, U. G. (2026). Vaccine‐Mediated Immunity in Survivors of Childhood Cancer: A Scoping Review. Pediatric Blood & Cancer, 73(7). https://doi.org/10.1002/1545-5017.70319

Vancouver

Junak S, Algave M, Beauchemin M, Creber RM, Bronas UG. Vaccine‐Mediated Immunity in Survivors of Childhood Cancer: A Scoping Review. Pediatric Blood & Cancer. 2026;73(7). doi:10.1002/1545-5017.70319

BibTeX
@article{Junak2026,
  author = {Junak, Sophie and Algave, Marcela and Beauchemin, Melissa and Creber, Ruth Masterson and Bronas, Ulf G},
  title = {Vaccine‐Mediated Immunity in Survivors of Childhood Cancer: A Scoping Review},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  volume = {73},
  number = {7},
  doi = {10.1002/1545-5017.70319}
}
Kostenlos starten →